Latest market data
| Close | 4.81 (-0.82% on the day; -16.2% over 5 sessions; -19.43% over 20 sessions) |
|---|---|
| Market cap | CNY 12.11 billion |
| P/E (TTM) | 19.13x (64th percentile over 5.2 years) |
| P/B (MRQ) | 1.92x (70th percentile over 5.2 years) |
| P/S (TTM) | 0.74x (94th percentile over 5.2 years) |
| 52-week range | 2.84 (2026-06-29) – 9.86 (2026-09-23) |
| Moving averages | MA5 5.1 / MA10 5.41 / MA20 5.46 / MA60 6.95 |
| MACD (12,26,9) | DIF -0.405, DEA -0.386, histogram -0.039 |
| RSI | RSI6 19.4 / RSI14 31.2 |
| Bollinger bands (20,2) | Upper 6.07 / middle 5.46 / lower 4.86 |
| Volume | 0.59x the 20-day average |
| One-week range (about 68% coverage) | 4.34 – 5.41 (-9.8% ~ +12.5%) |
| One-week range (about 95% coverage) | 4.01 – 6.3 (-16.6% ~ +31.0%) |
As of the 2026-11-18 close; calculated from daily price data (adjusted prices) and refreshed automatically each trading day. The one-week range reflects historical volatility only and is not a forecast. The report below was written on 2026-10-01; its prices and short-term scenarios reflect data at that time.
Harbin Pharmaceutical Group Co., Ltd. (600664)
Equity Research Report | Sector: Pharmaceutical Manufacturing & Distribution | Report Date: October 1, 2026 | Market Data and Technical Indicators as of September 30, 2026 Close
This report is automatically compiled and generated by AI based on public information, for reference only, and does not constitute investment advice.
Core Conclusion: Profit recovery has emerged, but cash flow and the industrial segment remain under pressure; valuation demands high growth delivery
| Key Data | Value |
|---|---|
| Closing Price (Daily Change) | RMB 7.4 (+3.64%) |
| Total Market Cap | Approx. RMB 18.637 billion |
| PE(TTM) | 36.39x |
| PB(MRQ) | 3.05x |
| 52-Week Range | RMB 2.84–9.86 |
| Turnover / Turnover Rate | Approx. RMB 3.910 billion / 20.61% |
Market data as of: Market data and technical indicators as of September 30, 2026 close
1. Key Investment Points
- Profit recovery outpacing revenue, but quality yet to be verified: 2026H1 revenue grew 2.10%, net profit attributable to parent grew 57.99%, non-recurring-adjusted profit grew 45.39%; gross margin declined approximately 0.67 percentage points YoY, and operating cash flow was negative.
- Retail growth not yet sufficient to offset industrial contraction: In 2025, pharmaceutical industrial revenue declined 8.52%, commercial revenue grew 3.32%; commercial retail grew 21.04%, serving as the primary support at this stage.
- Valuation at historical highs and requires growth delivery: September 30 close of RMB 7.40, PE-TTM 36.39x, PB 3.05x; PE at the 87th percentile, PB at the 98th percentile. Single institution target price RMB 9.16.
Market Expectations and Evidence
- Market is pricing in: 36.39x PE implies approximately 18% annual EPS growth over the next 10 years, higher than the single institution's 2026–28 EPS CAGR forecast of approximately 15.5%; the two time horizons are not entirely comparable.
- Evidence shows: H1 net profit attributable to parent and non-recurring-adjusted profit grew 57.99% and 45.39% respectively, but revenue grew only 2.10%, gross margin declined, and operating cash flow was negative. Profit recovery has emerged, but sustainability and cash realization remain to be verified.
Evidence bias: Bearish; Confidence: Medium
H1 profit rebound is clear, but revenue, gross margin, and cash flow have not improved in tandem; valuation is elevated, and the forecast comes from only one institution.
2. Business and Competitiveness
2.1 Business Structure
Produces and sells chemical drugs, traditional Chinese medicine, biologics, and health products, and conducts pharmaceutical wholesale, retail, and logistics through Renmin Tongtai.
| Business Segment | Revenue Share | Gross Margin | Revenue Growth | Key Points |
|---|---|---|---|---|
| Pharmaceutical Commercial | Approx. 64.8% (2025, estimated based on consolidated operating revenue) | 7.91% (2025) | 3.32% (2025 revenue YoY) | Retail revenue grew 21.04% YoY; DTP and prescription outflow business provide growth support; centralized procurement compresses price spreads. |
| Pharmaceutical Industrial | Approx. 36.0% (2025, estimated based on consolidated operating revenue) | 57.24% (2025) | -8.52% (2025 revenue YoY) | Health products, chemical preparations, and traditional Chinese medicine revenue all declined; biologics revenue grew 4.83%. |
2.2 Competitive Advantages
Competitive Advantage Strength: Weak
- Product coverage includes chemical drugs, traditional Chinese medicine, biologics, and health products; 2025 biologics gross margin was 72.72%, but revenue was only RMB 293 million.
- Renmin Tongtai operates pharmaceutical wholesale, retail, and logistics in Heilongjiang Province; 2025 pharmaceutical commercial revenue was RMB 10.339 billion, retail revenue grew 21.04%.
- 2025 R&D investment of RMB 204 million and 1,058 R&D personnel demonstrate R&D organizational capability and investment, but are not yet sufficient to prove commercialization barriers.
Main threats: Centralized procurement, medical insurance cost control, and competitive price pressure affect the industrial segment; commercial distribution has thin margins, and health product channel transformation and demand slowdown may also compress profitability.
2.3 Industry Chain Position and Profit Trends
- Procures chemical APIs, traditional Chinese medicinal materials, excipients, and packaging materials, using bidding, centralized procurement, strategic procurement, and mall platform procurement.
- In 2025, the top five suppliers accounted for 16.96% of total annual procurement, with the first accounting for 4.43%; this is at the group procurement level and does not equate to industrial raw material supplier concentration.
- Customers include medical institutions, pharmaceutical commercial customers, retail consumers, and e-commerce/health product channels; medical institutions and distribution channels are subject to centralized procurement, medical insurance cost control, and winning bid price constraints.
- Commercial segment spreads are relatively thin: 2025 wholesale medical customer gross margin was 6.87%, wholesale commercial customer gross margin was 3.50%.
- 2025 annual report disclosed that the top five customers accounted for 14.23% of total sales, with the first accounting for 3.88%; this is at the group level, top five customer names were not disclosed, and cannot represent single-segment concentration.
- As of end-2025, accounts receivable were RMB 4.387 billion, approximately 27.5% of full-year revenue and approximately 12.1x net profit attributable to parent; estimated turnover of approximately 100 days. Prepayments of RMB 190 million, inventory of RMB 2.061 billion; consolidated figures do not represent single-segment collection.
| Year | Gross Margin | Net Margin | Reason for Change |
|---|---|---|---|
| 2022 | 24.67% | 3.37% | At the low end of gross margin in this table; existing disclosures do not provide verifiable year-by-year driver breakdown. |
| 2023 | 26.21% | 3.30% | Main revenue growth, gross margin recovery; industrial health products and some pharmaceutical products grew, but structure diverged. |
| 2024 | 28.24% | 3.89% | Gross margin improved YoY; existing materials do not provide a breakdown sufficient to attribute to specific upstream/downstream factors. |
| 2025 | 25.98% | 2.26% | Both industrial and commercial gross margins declined, profitability under pressure from centralized procurement, medical insurance cost control, and competitive price pressure. |
The company occupies a position combining midstream manufacturing with regional distribution: the industrial segment has higher margins but declining revenue, while the commercial segment has large scale but thin margins. Improvement depends on high-margin product recovery and structural optimization, cost control, and increased retail/DTP share and operational efficiency. Historical profit margins for 2022–2023 have source caliber differences; net margin is calculated as net profit attributable to parent / operating revenue.
2.4 Industry and Peer Comparison
The company is in a mature business stage with parallel pharmaceutical manufacturing and distribution. In 2025, centralized procurement, medical insurance cost control, and health product channel transformation suppressed industrial segment revenue and gross margin, while retail/DTP growth was an important support for the commercial segment.
| Company | Positioning | Comparable Data | Difference from This Company |
|---|---|---|---|
| Kelun Pharmaceutical (002422) | Primarily chemical preparations, infusion products, etc. | 2025 revenue RMB 18.513 billion, gross margin 49.00%, PE-TTM approx. 35.53x | Revenue scale is similar, but business structure and profit drivers differ. |
| Livzon Pharmaceutical (000513) | Preparations, biologics, etc. | 2025 revenue RMB 12.020 billion, gross margin 65.90%, PE-TTM approx. 17.45x | Gross margin is notably higher; products and R&D structure are not one-to-one comparable. |
| China Resources Sanjiu (000999) | OTC, traditional Chinese medicine, and consumer health | 2025 revenue RMB 31.603 billion, gross margin 52.59%, PE-TTM approx. 12.29x | Some business is comparable, but scale is significantly larger. |
| Xinhua Pharmaceutical (000756) | Chemical drugs and APIs | 2025 revenue RMB 8.755 billion, gross margin 18.78%, PE— | Partially comparable to Harbin Pharma's chemical preparations business; historical PE on the same day could not be cross-verified. |
| Tongrentang (600085) | Branded traditional Chinese medicine | 2025 revenue RMB 17.256 billion, gross margin approx. 42.87%, PE-TTM approx. 33.56x | Traditional Chinese medicine/OTC business is partially comparable, but product structure and channels differ notably. |
Harbin Pharma has both pharmaceutical manufacturing and regional distribution; commercial scale is large and retail/DTP is growing relatively fast; the shortcomings are thin distribution margins and declining industrial revenue, with overall gross margin below most pharmaceutical and branded traditional Chinese medicine comparable companies. Comparable company PE is non-exchange data, for valuation reference only.
3. Financial Quality
3.1 Operating Performance
| Reporting Period | Operating Revenue | YoY | Net Profit Attributable to Parent | YoY | Non-Recurring-Adjusted YoY | Gross Margin |
|---|---|---|---|---|---|---|
| 2026 H1 | RMB 8.296 billion | +2.10% | RMB 410 million | +57.99% | +45.39% | 26.38% |
| 2025 | RMB 15.964 billion | -1.31% | RMB 362 million | -42.50% | -47.49% | 26.0% |
| 2024 | RMB 16.176 billion | +4.65% | RMB 629 million | +59.10% | +80.08% | Approx. 28.24% |
As of October 1, 2026; 2026 interim report is unaudited, gross margin calculated based on disclosed data.
In 2026 H1, profit recovery outpaced revenue, with non-recurring-adjusted growth lower than attributable to parent; non-recurring gains and losses were approximately RMB 55 million. Gross margin declined approximately 0.67 percentage points YoY, and operating cash flow remained negative.
3.2 Financial Health Check
| Indicator | Value | Assessment | Notes |
|---|---|---|---|
| Weighted Average ROE | 2025: 6.55%; 2026H1: 6.96% | Average | 2025 profitability declined notably YoY |
| Debt-to-Asset Ratio | 53.0% (2026 interim) | Average | Debt ratio exceeds half; short-term cash can cover borrowings |
| Operating Cash Flow / Net Profit Attributable to Parent | 2025: 1.22x; 2026H1: -0.11x | Watch | H1 cash flow was negative; need to track collections and seasonality |
| Accounts Receivable Turnover | 2025: 3.65x; 2026H1 annualized 3.61x | Watch | Accounts receivable growth exceeded contemporaneous revenue growth |
| Goodwill / Net Assets Attributable to Parent | 0.64% (2026 interim) | Good | Goodwill scale is relatively small vs. net assets |
4. Valuation and Market Expectations
4.1 Valuation Levels
| Indicator | Current | Own History | Peer Comparison |
|---|---|---|---|
| PE(TTM) | 36.39x | 87th percentile over past 5.2 years (median 17.72x) | Pharmaceutical manufacturing median PE approx. 36.65x (2026-09-23, rough reference) |
| PB(MRQ) | 3.05x | 98th percentile over past 5.2 years (median 1.81x) | — |
| PS(TTM) | 1.16x | 98th percentile over past 5.2 years (median 0.58x) | — |
| Dividend Yield | 0% (valuation snapshot caliber) | — | — |
Valuation multiples calculated programmatically based on September 30, 2026 closing data (trailing twelve months caliber)
Market-implied expectations: At the current 36.39x PE, if investors require an 8% annualized return and a 15x PE valuation after 10 years, EPS would need to grow approximately 18.0% annually (excluding dividends, conservative), which can be compared with the consensus growth forecast below.
September 30 PE-TTM 36.39x, at the 87th percentile over past 5.2 years; PB 3.05x and PS 1.16x are both at the 98th percentile, notably above their respective historical medians. Price implies long-term EPS growth of approximately 18% annually, higher than the single institution's 2026–28 forecast of approximately 15.5%; if profit recovery cannot be sustained, valuation buffer is limited.
4.2 Consensus Forecast
| Year | Operating Revenue | Net Profit Attributable to Parent | Net Profit Growth | Earnings Per Share (EPS) |
|---|---|---|---|---|
| 2026 | RMB 16.403 billion | RMB 607 million | — | RMB 0.24 |
| 2027 | RMB 16.939 billion | RMB 699 million | — | RMB 0.28 |
| 2028 | RMB 17.491 billion | RMB 806 million | — | RMB 0.32 |
Only 1 institution (Huatai Securities), not multi-institution consensus; research report date indexed as August 26 or 28, 2026, forecast content consistent.
4.3 Institutional Views
Only Huatai Securities provides recent coverage: target price RMB 9.16, range and average both RMB 9.16; aggregation page date marked as August 26 or 28, 2026.
| Institution | Rating | Date | Notes |
|---|---|---|---|
| Huatai Securities | Buy | 2026-08-26/28 | Target price RMB 9.16; single institution sample |
5. Catalysts and Recent Events
5.1 Upcoming Key Milestones
| Time | Event | Focus |
|---|---|---|
| 2026-10-27 | Scheduled disclosure of 2026 Q3 report | Focus on pharmaceutical industrial growth, non-recurring-adjusted profit, and impact of one-time gains; note any notable slowdown vs. interim report trends. |
| Within 2026 (specific implementation dates per local notices) | 12th batch centralized procurement local implementation | Focus on contract signing, local procurement launch, and actual sales; if implementation lands with positive sales contribution, if continued non-execution then realization delayed. |
| From September 1, 2026, approximately 6-month observation | Sales conversion of new varieties added to the new essential drug list | Focus on terminal sales changes for new specifications; the company has not disclosed a quantified realization timetable, and inclusion in the list cannot yet be treated as earnings increment. |
5.2 Recent Important Events
- 2026-08-26 Interim report net profit attributable to parent grew 57.99% (Positive): H1 revenue RMB 8.296 billion, net profit attributable to parent RMB 410.3 million, up 2.10% and 57.99% YoY respectively; non-recurring-adjusted net profit grew approximately 45.39%. Profit growth was relatively fast but included approximately RMB 35.69 million in gains from disposal of idle equipment.
- 2026-08-06 Two preparations selected for 12th batch centralized procurement (Positive): Ceftazidime-avibactam sodium for injection and vonoprazan fumarate tablets proposed for selection, procurement cycle through end-2029; the company stated that at the time of announcement the products had not yet been sold, and contracts, local implementation, and revenue contribution remain to be realized.
- 2026-07-14 Six new varieties added to the new essential drug list (Positive): The company and its affiliates had 118 specifications included in the 2026 edition list, with 6 new varieties and 10 specifications added; the list took effect on September 1. The company stated no significant short-term earnings impact is expected, and long-term effects depend on market and terminal demand.
- 2026-09-23 Stock price abnormal fluctuation warning of valuation risk (Negative): The company disclosed consecutive daily limit-ups on September 21–22, with cumulative gain of 21.07%; as of September 21, static PE was 57.46x, higher than the industry's 27.66x as cited, and stated no undisclosed material matters requiring disclosure were found.
6. Bull-Bear Divergence and Risks
6.1 Bull Case
- 2026H1 net profit attributable to parent grew 57.99%, non-recurring-adjusted grew 45.39%, with profit recovery significantly exceeding the 2.10% revenue growth.
- 2025 commercial retail revenue grew 21.04%, pharmaceutical commercial revenue grew 3.32%, with retail/DTP providing incremental support for the commercial segment.
- Two preparations proposed for selection in the 12th batch centralized procurement, 118 specifications included in the new essential drug list; if implemented and converted to sales, product coverage can be expanded.
6.2 Bear Case
- 2025 pharmaceutical industrial revenue declined 8.52%, with health products, chemical preparations, and traditional Chinese medicine revenue all declining; the industrial segment has not yet reversed.
- PE-TTM 36.39x at the 87th percentile over past 5.2 years, PB and PS both at the 98th percentile, valuation already at its own historical highs.
- Commercial wholesale customer gross margin is only 3.50%, pharmaceutical commercial revenue share is approximately 64.8%; distribution business is large in scale but has limited profit elasticity.
6.3 Other Risks
- 2026H1 operating cash flow / net profit attributable to parent was -0.11x, accounts receivable turnover annualized at 3.61x; continued weakening of collections will tie up capital and increase impairment pressure.
- The two proposed centralized procurement products had not yet been sold at announcement; if local implementation or contract signing is delayed, expected revenue contribution will be pushed back.
- The company stated no significant short-term earnings impact is expected from the new essential drug list; if terminal demand conversion for newly added varieties is insufficient, list expansion will struggle to generate profit increment.
7. Tracking Checklist
| Tracking Indicator | Current | Verify Bull Case | Verify Bear Case |
|---|---|---|---|
| Q3 report non-recurring-adjusted profit | Scheduled disclosure October 27, 2026; H1 non-recurring-adjusted +45.39% | Non-recurring-adjusted growth continues positive, and gap with attributable-to-parent growth narrows | Non-recurring-adjusted notably slows or attributable-to-parent growth mainly relies on one-time gains |
| Pharmaceutical industrial revenue | 2025 declined 8.52% YoY | Subsequent quarterly revenue resumes YoY growth, gross margin stops declining | Revenue continues to decline and gross margin further deteriorates |
| Operating cash flow and collections | H1 cash flow / net profit attributable to parent -0.11x; receivables turnover annualized 3.61x | Full-year operating cash flow turns positive and covers net profit attributable to parent | Full-year operating cash flow remains negative or turnover below 3.61x |
| Centralized procurement and essential drug sales realization | Two preparations proposed for selection; no quantified sales data for newly added list varieties | Complete local implementation and disclose actual sales contribution | Implementation delayed, or no improvement in sales of newly added list varieties |
8. Stock Price and Short-Term Outlook (Next One Week, Scenario Analysis, For Reference Only)
⚠️ Risk Warning: The following is a subjective scenario analysis based on September 30 closing data; weights are heuristic judgments, not statistical probabilities, and do not constitute investment advice.
8.1 Technical Overview
Stock price remains below the RMB 7.81–7.87 moving average dense zone, MACD histogram weakening; the September 30 volume-driven rally only constitutes a rebound observation signal. The company warned on September 23 of relatively large short-term gains and rapid decline risk, with no confirmable new major catalyst observed.
| Indicator | Value | Interpretation |
|---|---|---|
| MA5/MA10/MA20/MA60 | MA5 7.81 / MA10 7.87 / MA20 7.81 / MA60 7.08 | Close below short-term moving average dense zone, MA60 below. |
| MACD (DIF/DEA/Histogram) | DIF -0.003 / DEA 0.091 / Histogram -0.187 | Histogram further weakened vs. previous day. |
| RSI6/RSI14 | RSI6 41.1 / RSI14 46.1 | Short-term momentum weak, not yet in obvious oversold territory. |
| Bollinger Upper/Middle/Lower Bands | Upper 9.2 / Middle 7.81 / Lower 6.41 | Middle band close to short-term moving averages, lower band as reference support. |
| Past 5-Day / 20-Day Change | -18.50% / -22.02% | Recent pullback relatively large, single-day rebound insufficient to confirm reversal. |
8.2 Key Price Levels
| Level | Range | Notes |
|---|---|---|
| Short-Term Resistance | RMB 7.80–8.00 | Corresponds to short-term moving average dense zone; only after volume-backed stabilization can higher resistance zones be observed. |
| First Support | RMB 7.00–7.10 | Reference MA60 and above the 20-day low; a breach may retest approximately RMB 6.92. |
| Strong Support | RMB 6.40–6.90 | Reference 20-day low and Bollinger lower band; an effective breach would increase technical risk, with near-term downside support unclear. |
8.3 One-Week Range Calculated from Historical Volatility
Using the September 30, 2026 price of RMB 7.4 as the base, using the return distribution over the past 300 trading days (scaled to current index-weighted daily volatility of approximately 5.8%, retaining this stock's own frequency of large gains and declines) to project the closing price range for the next 5 trading days:
| Coverage Probability | Price Range | Relative to Base |
|---|---|---|
| Approx. 68% | RMB 6.42–8.66 | -13.2% to +17.0% |
| Approx. 95% | RMB 5.29–10.64 | -28.5% to +43.8% |
This range only reflects this stock's recent volatility magnitude and does not include directional judgment; in the event of major announcements or sharp market declines, actual movements may still exceed the range.
8.4 Next One-Week Scenarios (Subjective Weights, Not Statistical Probabilities)
- Range-bound consolidation (relatively higher weight, approx. 50%): Next one-week close reference RMB 6.90–8.00; holding RMB 6.92–7.08 but not sustainably breaking above RMB 7.80–8.00 on volume, range-bound consolidation bias.
- Weaker decline (medium weight, approx. 30%): Next one-week close reference RMB 6.40–7.10; if breaking below RMB 6.92–7.08 with sector weakness or volume-driven decline in the stock, may test near the Bollinger lower band.
- Rebound strengthening (relatively lower weight, approx. 20%): Next one-week close reference RMB 7.80–8.60; requires volume-backed break above RMB 7.80–8.00, with pharmaceutical sector not notably weak and capital divergence converging.
8.5 Capital and Liquidity
Over recent verifiable trading days, turnover rate was approximately 17.15%–20.61%, turnover approximately RMB 3.121 billion–4.120 billion; main capital data varies significantly across data providers. As of June 30, 2026, the top ten shareholders collectively held approximately 51.79%, with the controlling shareholder holding 46.58%; no public funds, social security, or QFII appear in the list; Hong Kong Stock Connect registration does not represent final holder category. Shareholder data lags approximately three months; high turnover accompanies rapid gains and declines, active trading does not equal stable absorption, and chase-price slippage risk increases.
If single-day turnover exceeds RMB 4.5 billion and close stands above RMB 7.80–8.00, this can be viewed as stronger volume-price confirmation than recent norm; volume without recovery does not confirm strengthening.
The above scenario analysis is based on September 30, 2026 closing data and historical price and technical indicator calculations; short-term stock prices are also affected by multiple factors including news flow, capital flows, and overall market environment; technical indicators themselves have lag and limitations, do not guarantee future actual movements, and do not constitute buy or sell advice; please combine with the latest market information to make independent judgments and bear investment risks yourself.
Sources
- 哈药集团股份有限公司2025年年度报告
- 哈药股份(600664)_公司公告_哈药股份:2025年年度报告新浪财经_新浪网
- 哈药股份(600664)年度数据分析-中商产业研究院数据库-中商情报网
- static.cninfo.com.cn (PDF filing)
- 哈药股份(600664)_公司公告_哈药股份:2024年年度报告新浪财经_新浪网
- 公司公告_哈药股份:2026年半年度业绩预增公告新浪财经_新浪网
- 公司公告_哈药股份:2025年年度报告新浪财经_新浪网
- 哈药股份(600664)_股票行情,行情首页_中财网
- 哈药股份(600664) 盈利预测_F10_同花顺金融服务网
- 哈药股份(600664) 盈利预测_F10_同花顺金融服务网
- 哈药股份 7.40 +3.64%(0.26)股票价格-行情-走势图-行情-金融界
- 哈药股份(600664)_公司公告_哈药股份:2026年半年度报告新浪财经_新浪网
- 哈药股份(600664)_公司公告_哈药股份:2026年半年度业绩预增公告新浪财经_新浪网
- 新潮实业(600777)董事会决议暨召开股东大会的通知
- 新潮实业(600777)董事会决议暨召开股东大会的通知
- 新潮实业(600777)董事会决议暨召开股东大会的通知
- 哈药股份(600664)_公司公告_哈药股份:股票交易异常波动公告新浪财经_新浪网
- 国家医疗保障局 国家组织集中采购 关于公布第12批国家组织药品集中带量采购中选结果(GY-YD2026-1)的通知
- 哈药集团股份有限公司
- 哈药股份(600664)个股分析_牛叉诊股_同花顺财经
- 哈药股份(600664)_股票行情,行情首页_中财网
- 哈药股份(600664)主要股东_新浪财经_新浪网
This report is automatically retrieved, compiled, and generated by AI based on public channel information; information is as of Market data and technical indicators as of September 30, 2026 close, and timeliness differences may exist; specific data please refer to the company's official announcements and authoritative data terminals. This report is for information compilation and research reference only, does not constitute any investment advice, and investors should make independent judgments and bear investment risks themselves.
Model value range, DCF / industry models, comparable-company checks, confidence and key assumptions
- Price
- HK$301.00
- Low
- HK$313.08
- Base
- HK$433.53
- High
- HK$566.80